Kontrol Delivers Two BioCloud Units to Health Canada for Testing and Adds Middle East Distribution Partner
Kontrol Technologies Corp. a leader in smart buildings and cities through IoT, Cloud and SaaS technology is pleased to announce that it has delivered two BioCloud units to Health Canada for testing and has added a Middle East distribution partner with regional exclusivity.
Recommended AI News: Vendasta Announces Historic $119.5 Million Round to Revolutionize Small Business Technology
Testing with Health Canada
The two BioCloud units were delivered in May 2021 to Health Canada’s National Microbiology Level 4 laboratory. The testing is carried out at the request of several interested government agencies and at no cost to Kontrol. The testing is anticipated to include efficiencies and detection of SARs-COV-2 and its variants under various control conditions. Testing has commenced with results anticipated in July 2021.
Upon receipt of final testing and results the Company will announce and publish those results on its website, subject to any regulatory approval which may be required.
Recommended AI News: Starburst Announces New Product Release Including Advanced Lakehouse Analytics Capabilities
New Distribution
Kontrol BioCloud has entered into an exclusive distribution agreement with the Royal Health Group, following a recent positive pilot completion as per the press release dated May 25th, 2021. The Royal Health Group is led by Dr. Mohammed Al Seiari, a recognized health care leader in the United Arab Emirates (“UAE”). The Royal Health Group provides COVID-19 testing facilities and other health care services throughout the region.
“We are very impressed with the BioCloud technology,” said Dr. Mohammed Al Seiari. “The BioCloud technology can play an important role in supporting the detection of viruses and pathogens which can help provide the confidence we need to return to normal as the global economy seeks to re-open.”
Under the terms of the agreement Royal Health Group will have regional exclusivity for the UAE and the parties will negotiate the minimum number of annual units of BioCloud sales required to maintain the exclusivity. The exclusive period is for one year with an option to renew.
Kontrol BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
Recommended AI News: Orange Marketing Becomes a Diamond HubSpot Solutions Partner
Comments are closed.